Tag
This study reveals that younger, non-Hispanic White patients with fewer comorbidities and lower socioeconomic vulnerability are more likely to receive antiamyloid medications for Alzheimer’s, while higher comorbidity predicts lower initial
This study reveals that midlife plasma p-tau181 predicts faster memory decline over 11 years, highlighting a long prodromal phase of Alzheimer’s disease. Late-life biomarkers p-tau181, NfL, and GFAP correlate with accelerated cognitive decl
A large-scale UK cohort study found no strong associations between antibodies against multiple common infections and key Alzheimer’s disease neuropathologies, though possible interactions with APOE ε4 genotype and education warrant further
Early disclosure of plasma p-tau217 and NfL biomarkers significantly improves diagnostic confidence and clinical decisions in cognitive decline without increasing emotional distress, supporting their integration into routine memory clinic c
This review synthesizes evidence on clinical and biological factors linked to discordance between plasma p-tau217 and standard AD biomarkers, highlighting implications for diagnosis, patient stratification, and future biomarker development.
This review synthesizes evidence linking hearing loss to regional brain amyloid deposition, highlighting recent in vivo PET findings, meta-analytic data on AD neuropathology, and amyloid-related inner ear pathology, discussing potential mec
This longitudinal study investigates plasma biomarker dynamics in Alzheimer’s patients treated with lecanemab, revealing distinct biomarker trajectories that reflect amyloid clearance, tau modulation, and immune responses, offering in
This study introduces a standardized 5-class framework for tau PET imaging to better detect and stage Alzheimer’s disease, improving early diagnosis and patient stratification across different tracers.
This pooled analysis of seven multi-ethnic cohorts demonstrates the combined prognostic value of plasma phosphorylated tau 217 concentrations and APOE-ε4 genotype for predicting risk and timing of cognitive impairment, emphasizing biomarker
Longitudinal analysis of blood proteins reveals distinctive trajectories and associations with cognitive decline in adults with Down syndrome, shedding light on Alzheimer’s disease pathophysiology in this high-risk group.
A multiprotein plasma panel improves detection of advanced neocortical tau pathology in Alzheimer’s disease risk individuals beyond p-tau217 alone, enhancing patient stratification and clinical trial selection.
This review synthesizes evidence linking NOAC use to slower cognitive decline and improved clinical outcomes in patients with atrial fibrillation and Alzheimer’s disease, highlighting advantages over warfarin and non-use.
Plasma phosphorylated tau biomarkers overlap in Alzheimer’s and prion diseases, risking diagnostic confusion. The NfL/p-tau217 ratio emerges as an accurate plasma biomarker to distinguish prion diseases from Alzheimer’s, improving diagnosti
This review examines the impact of traumatic brain injury on the accuracy of Alzheimer disease blood biomarkers, highlighting reduced diagnostic performance in TBI-affected populations and the implications for clinical interpretation.
Higher parity in cognitively unimpaired postmenopausal women with positive β-amyloid status is linked to accelerated cognitive decline and hippocampal volume reduction, suggesting parity modulates resilience to Alzheimer’s pathology in prec
A genome-wide study identified three genetic modifiers of autosomal dominant Alzheimer’s disease, linking them to disease risk, earlier onset, and biomarker changes involving amyloid, tau, TDP-43, and brain aging.
Women with high amyloid-β show higher p-tau217 levels and faster tau accumulation than men, leading to greater cognitive decline. This sex-specific tau response may redefine preclinical Alzheimer’s diagnostics and therapeutics.
Women exhibit higher plasma p-tau217 levels and tau aggregation than men in amyloid-positive individuals, suggesting sex-specific pathways in Alzheimer’s disease progression.
This review synthesizes recent clinical evidence on the integration of plasma p-tau217 and eMTBR-tau243, highlighting how sequential biomarker testing improves the diagnosis of symptomatic Alzheimer’s disease and predicts longitudinal cogni
A large-scale analysis of the VA Million Veteran Program reveals that TBI, depression, and specific military environmental exposures significantly elevate the 10-year risk of Alzheimer’s and related dementias, highlighting critical targets
